Novartis AG ADR (NVS)vsRegenxbio Inc (RGNX)
NVS
Novartis AG ADR
$137.16
+1.36%
HEALTHCARE · Cap: $260.70B
RGNX
Regenxbio Inc
$8.53
-0.35%
HEALTHCARE · Cap: $590.16M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 32392% more annual revenue ($56.69B vs $174.48M). NVS leads profitability with a 22.5% profit margin vs -112.6%. RGNX appears more attractively valued with a PEG of 0.26. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
RGNX
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for RGNX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Growing faster than its price suggests
Revenue surging 405.7% year-over-year
Strong operational efficiency at 27.1%
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -273.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : RGNX
The strongest argument for RGNX centers on PEG Ratio, Revenue Growth, Operating Margin. Revenue growth of 405.7% demonstrates continued momentum. PEG of 0.26 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : RGNX
The primary concerns for RGNX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while RGNX is a hypergrowth play — different risk/reward profiles.
RGNX carries more volatility with a beta of 0.93 — expect wider price swings.
RGNX is growing revenue faster at 405.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 50/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Regenxbio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?